Gamma delta CAR-T cell therapy - Cytomed Therapeutics
Alternative Names: Chimeric antigen receptor (CAR) gene grafted gamma delta T cells therapy - Cytomed Therapeutics/Hangzhou CNK Therapeutics; GDNKT- CAR-T-Cell-therapy - Cytomed-TherapeuticsLatest Information Update: 01 Feb 2024
At a glance
- Originator CytoMed Therapeutics
- Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Cancer
Most Recent Events
- 29 Jan 2024 CytoMed Therapeutics has patent protection for chimeric antigen receptor gamma delta T cell (“CAR-γδ T cell”) technology in Malaysia
- 05 Dec 2023 CytoMed Therapeutics signed Heads of Agreement with CytoMed Therapeutics China to co develop gamma delta CAR-T cell therapy in China for cancer
- 05 Dec 2023 CytoMed Therapeutics signs a Memorandum of Understanding with Bionex solutions for gamma delta CAR-T cell therapy